Literature DB >> 21241247

Adverse effects of tacrolimus in renal transplant patients from living donors.

Nailya Bulatova1, Al-Motassem Yousef, Ghada Al-Khayyat, Hisham Qosa.   

Abstract

INTRODUCTION: The main objectives of this study were to estimate the prevalence of and the risk factors for the adverse effects of tacrolimus-based immunosuppression in patients who obtained renal transplant from living donors.
METHODS: A multicenter cross-sectional observational study in 154 kidney transplant patients who received grafts from living donors.
RESULTS: Large proportion of patients had hypertension (83%) and hyperlipidemia (53%); 27% had posttransplant diabetes mellitus. Patients had on average two chronic diseases. Tremor was present in 40%, neurologic toxicity in 45%, and anemia in 51.5% of patients. The average number of adverse effects was 3.52 ± 1.57. In multivariate analysis some adverse effects were related to tacrolimus concentration, duration of treatment, number of medications or medical problems. In linear regression analysis correlation was found, among the others, between diastolic blood pressure and tacrolimus concentration, and inverse correlation between erythrocyte count and duration of treatment.
CONCLUSION: There is a significant prevalence of tacrolimus adverse effects and supratherapeutic TAC blood concentrations in Jordanian renal transplant patients in spite of using low TAC doses and overall adequate renal function.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21241247     DOI: 10.2174/157488611794480043

Source DB:  PubMed          Journal:  Curr Drug Saf        ISSN: 1574-8863


  6 in total

1.  Management of hypertension and factors affecting its control in Jordanian renal transplant recipients.

Authors:  Nailya Bulatova; Al-Motassem Yousef; Hisham Qusa; Ghada Al Khayat; Wadad Ailabouni; Ayman Wahbeh; Muhammad Al-Ulemat
Journal:  Int J Clin Pharm       Date:  2012-04-03

2.  Tremor induced by Calcineurin inhibitor immunosuppression: a single-centre observational study in kidney transplanted patients.

Authors:  R Erro; Ruggero Bacchin; F Magrinelli; P Tomei; C Geroin; G Squintani; A Lupo; G Zaza; M Tinazzi
Journal:  J Neurol       Date:  2018-05-18       Impact factor: 4.849

3.  Bioavailability of once-daily tacrolimus formulations used in clinical practice in the management of De Novo kidney transplant recipients: the better study.

Authors:  Constantino Fernandez Rivera; María Calvo Rodríguez; José Luís Poveda; Julio Pascual; Marta Crespo; Gonzalo Gomez; Sheila Cabello Pelegrin; Javier Paul; Ricardo Lauzurica; Mònica Perez Mir; Francesc Moreso; Manel Perelló; Amado Andres; Esther González; Ana Fernandez; Alicia Mendiluce; Beatriz Fernández Carbajo; Ana Sanchez Fructuoso; Natividad Calvo; Alejandro Suarez; Gabriel Bernal Blanco; Antonio Osuna; M Carmen Ruiz-Fuentes; Edoardo Melilli; Nuria Montero Perez; Ana Ramos; Beatriz Fernández; Verónica López; Domingo Hernandez
Journal:  Clin Transplant       Date:  2021-12-17       Impact factor: 3.456

4.  A four-drug combination therapy consisting of low-dose tacrolimus, low-dose mycophenolate mofetil, corticosteroids, and mizoribine in living donor renal transplantation: A randomized study.

Authors:  Tian-Zhong Yan; Xiao-Qiang Wu; Lu Rong
Journal:  SAGE Open Med       Date:  2016-05-11

5.  Switching STudy of Kidney TRansplant PAtients with Tremor to LCP-TacrO (STRATO): an open-label, multicenter, prospective phase 3b study.

Authors:  Anthony Langone; Steven M Steinberg; Roberto Gedaly; Laurence K Chan; Tariq Shah; Kapil D Sethi; Vincenza Nigro; John C Morgan
Journal:  Clin Transplant       Date:  2015-08-06       Impact factor: 2.863

6.  Localization of drug biodistribution in a 3D-bioengineered subcutaneous neovascularized microenvironment.

Authors:  Simone Capuani; Nathanael Hernandez; Jesus Paez-Mayorga; Prashant Dogra; Zhihui Wang; Vittorio Cristini; Corrine Ying Xuan Chua; Joan E Nichols; Alessandro Grattoni
Journal:  Mater Today Bio       Date:  2022-08-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.